RU2016141621A - Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин - Google Patents
Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин Download PDFInfo
- Publication number
- RU2016141621A RU2016141621A RU2016141621A RU2016141621A RU2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A RU 2016141621 A RU2016141621 A RU 2016141621A
- Authority
- RU
- Russia
- Prior art keywords
- aluminum
- immunogen
- aluminum salt
- adsorbed
- mpla
- Prior art date
Links
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 title claims 6
- 229910052782 aluminium Inorganic materials 0.000 title claims 6
- 229960005486 vaccine Drugs 0.000 title claims 3
- 230000036039 immunity Effects 0.000 title 1
- 238000005728 strengthening Methods 0.000 title 1
- 230000002163 immunogen Effects 0.000 claims 32
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 26
- 238000000034 method Methods 0.000 claims 21
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 15
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 5
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 241000606768 Haemophilus influenzae Species 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 201000005702 Pertussis Diseases 0.000 claims 2
- 208000000474 Poliomyelitis Diseases 0.000 claims 2
- 206010037742 Rabies Diseases 0.000 claims 2
- 206010043376 Tetanus Diseases 0.000 claims 2
- 208000037386 Typhoid Diseases 0.000 claims 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 2
- 229940103272 aluminum potassium sulfate Drugs 0.000 claims 2
- 206010013023 diphtheria Diseases 0.000 claims 2
- 208000005252 hepatitis A Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 claims 2
- 229960000814 tetanus toxoid Drugs 0.000 claims 2
- 201000008297 typhoid fever Diseases 0.000 claims 2
- 108700010908 HIV-1 proteins Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461969905P | 2014-03-25 | 2014-03-25 | |
| US61/969,905 | 2014-03-25 | ||
| PCT/US2014/045940 WO2015147899A1 (en) | 2014-03-25 | 2014-07-09 | Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016141621A true RU2016141621A (ru) | 2018-04-25 |
| RU2016141621A3 RU2016141621A3 (https=) | 2018-05-11 |
Family
ID=51302762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016141621A RU2016141621A (ru) | 2014-03-25 | 2014-07-09 | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170165358A1 (https=) |
| EP (1) | EP3122379A1 (https=) |
| JP (1) | JP2017509713A (https=) |
| KR (1) | KR20170016315A (https=) |
| CN (1) | CN106535929A (https=) |
| AU (1) | AU2014388299A1 (https=) |
| BR (1) | BR112016021692A2 (https=) |
| CA (1) | CA2943050A1 (https=) |
| MX (1) | MX2016012166A (https=) |
| RU (1) | RU2016141621A (https=) |
| SG (2) | SG10201808312YA (https=) |
| WO (1) | WO2015147899A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| EP3484441A4 (en) | 2016-07-15 | 2020-03-18 | President and Fellows of Harvard College | GLYCOLIPID COMPOSITIONS AND METHOD FOR USE |
| JP7385206B2 (ja) * | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | 免疫賦活剤 |
| CA3189004A1 (en) | 2020-07-22 | 2022-01-27 | 3H Bio. Co., Ltd. | A peptide used for immunotherapeutics |
| WO2022081707A1 (en) | 2020-10-13 | 2022-04-21 | The Government Of The United States, As Represented By The Secretary Of The Army | Sars-cov-2 dna vaccine and method of administering thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08506592A (ja) * | 1993-02-19 | 1996-07-16 | スミスクライン・ビーチャム・コーポレイション | ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物 |
| WO1994019013A1 (en) * | 1993-02-19 | 1994-09-01 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| ATE157882T1 (de) * | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| US20090214592A1 (en) * | 2005-02-16 | 2009-08-27 | O'hagan Derek | Adjuvant composition comprising aluminium phosphate and 3D-MPL |
| BRPI0811228A2 (pt) * | 2007-05-24 | 2014-10-21 | Glaxonsmithkline Biolog S A | Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica. |
| SG184188A1 (en) * | 2010-03-26 | 2012-10-30 | Glaxosmithkline Biolog Sa | Hiv vaccine |
-
2014
- 2014-07-09 CN CN201480077507.5A patent/CN106535929A/zh active Pending
- 2014-07-09 RU RU2016141621A patent/RU2016141621A/ru not_active Application Discontinuation
- 2014-07-09 KR KR1020167025974A patent/KR20170016315A/ko not_active Withdrawn
- 2014-07-09 JP JP2017502571A patent/JP2017509713A/ja active Pending
- 2014-07-09 WO PCT/US2014/045940 patent/WO2015147899A1/en not_active Ceased
- 2014-07-09 CA CA2943050A patent/CA2943050A1/en not_active Abandoned
- 2014-07-09 MX MX2016012166A patent/MX2016012166A/es unknown
- 2014-07-09 AU AU2014388299A patent/AU2014388299A1/en not_active Abandoned
- 2014-07-09 BR BR112016021692A patent/BR112016021692A2/pt not_active Application Discontinuation
- 2014-07-09 EP EP14750386.6A patent/EP3122379A1/en not_active Withdrawn
- 2014-07-09 SG SG10201808312YA patent/SG10201808312YA/en unknown
- 2014-07-09 US US15/127,076 patent/US20170165358A1/en not_active Abandoned
- 2014-07-09 SG SG11201607404PA patent/SG11201607404PA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015147899A1 (en) | 2015-10-01 |
| JP2017509713A (ja) | 2017-04-06 |
| KR20170016315A (ko) | 2017-02-13 |
| CA2943050A1 (en) | 2015-10-01 |
| MX2016012166A (es) | 2017-03-15 |
| AU2014388299A1 (en) | 2016-10-20 |
| SG11201607404PA (en) | 2016-10-28 |
| CN106535929A (zh) | 2017-03-22 |
| EP3122379A1 (en) | 2017-02-01 |
| BR112016021692A2 (pt) | 2017-08-15 |
| RU2016141621A3 (https=) | 2018-05-11 |
| SG10201808312YA (en) | 2018-10-30 |
| US20170165358A1 (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016141621A (ru) | Способы усиления эффективности иммуностимуляции адсорбированных на соли алюминия вакцин | |
| HRP20160816T1 (hr) | Upotreba virusa influence i emulzije ulja u vodi kao adjuvansa radi poticanja t-stanica cd4 i/ili poboljšanog odgovora memorijskih b-stanica | |
| JP2011504486A5 (https=) | ||
| FI3246044T4 (fi) | Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
| JP2014532620A5 (https=) | ||
| RU2014140521A (ru) | Адъювантные составы бустерных вакцин | |
| JP2006527762A5 (https=) | ||
| JP2014506916A5 (https=) | ||
| CA2400468A1 (en) | Proteosome influenza vaccine | |
| RU2017145963A (ru) | Составы вакцин против неоплазии и способы их получения | |
| JP2009519309A5 (https=) | ||
| JP2015509522A5 (https=) | ||
| JP2018521028A5 (https=) | ||
| RU2008119501A (ru) | Функциональные вирусоподоюные частицы гриппа (vlps) | |
| MY126588A (en) | Intranasal influenza virus vaccine | |
| RU2013114980A (ru) | Вакцинная композиция | |
| JP5712126B2 (ja) | 遅延型追加刺激免疫処置に対する迅速な応答 | |
| Parodi et al. | Inactivated influenza vaccines: recent progress and implications for the elderly | |
| JP2009539965A5 (https=) | ||
| RU2017129340A (ru) | Композиции nеisseria мeningitidis и способы их получения | |
| JP2012506421A5 (https=) | ||
| JP2021522296A5 (https=) | ||
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181008 |